Remove Bioavailability Remove Genetic Disease Remove RNA
article thumbnail

Jupiter Neurosciences Makes Way in CNS Treatments with $11M IPO

XTalks

Jotrol overcomes these barriers using patented micellar technology, enhancing bioavailability and enabling therapeutically effective doses. CAMP4’s RNA-based therapies focus on genetic diseases like urea cycle disorders, while Rapport’s small molecules aim to address epilepsy, pain and bipolar disorder.